Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Barbara Ann Centeno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-7668-2748; OpenAlex author ID A5007883302. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: 3 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 21

  1. Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-ras G12D Inhibition in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.041↗
  2. Intraoperative Guidance of Pancreatic Cancer Resection Using a Toll-like Receptor 2-Targeted Fluorescence Molecular Imaging Agent. Co-author DOI 10.1158/2767-9764.crc-24-0244↗
  3. L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy. Co-author DOI 10.3390/biomedicines12020461↗
  4. RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing. Co-author DOI 10.1038/s41467-023-44126-w↗
  5. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  6. Case Report of Isolated Gastric Metastasis of Pancreatic Cancer From a Diagnostic Biopsy: Management of a Rare Oncologic Entity. Co-author DOI 10.1177/1073274820904042↗
  7. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy… Co-author DOI 10.1080/0284186x.2016.1256497↗
  8. Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pai.0000000000000368↗
  9. δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. First author DOI 10.18632/oncotarget.15767↗
  10. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-015-5006-1↗
  11. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. Last author DOI 10.3978/j.issn.2078-6891.2015.075↗
  12. EGR-1/Bax pathway plays a role in vitamin E δ-tocotrienol-induced apoptosis in pancreatic cancer cells. Co-author DOI 10.1016/j.jnutbio.2015.02.008↗
  13. Annexin A8 Is a Prognostic Marker and Potential Therapeutic Target for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000218↗
  14. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0133562↗
  15. A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. Co-author DOI 10.1016/j.cgh.2014.02.038↗
  16. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Co-author DOI 10.1158/1535-7163.mct-12-0719↗
  17. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. First author DOI 10.1158/1940-6207.capr-13-0157↗
  18. SLC5A8 nuclear translocation and loss of expression are associated with poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31823f429f↗
  19. Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. Co-author DOI 10.1593/neo.121044↗
  20. Lessons learned from a complete remission of advanced metastatic pancreatic ductal adenocarcinoma. Co-author PMID 22706548↗
  21. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. Co-author DOI 10.1002/jso.21954↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mokenge Peter Malafa · 13 shared papers, 2011–2026 · strength 0.99
  2. Kazim M. Husain · 5 shared papers, 2013–2017 · strength 0.28
  3. Krystal Villalobos-Ayala · 1 shared paper, 2026 · strength 0.24
  4. Palanisamy Nallasamy · 1 shared paper, 2026 · strength 0.24
  5. Pranita Atri · 1 shared paper, 2026 · strength 0.24
  6. Jesse L. Cox · 1 shared paper, 2026 · strength 0.24
  7. Imran Khan · 1 shared paper, 2026 · strength 0.24
  8. Namita Bhyravbhatla · 1 shared paper, 2026 · strength 0.24
  9. Saravanakumar Marimuthu · 1 shared paper, 2026 · strength 0.24
  10. Zahraa Wajih Alsafwani · 1 shared paper, 2026 · strength 0.24
  11. Margaret A. Park · 1 shared paper, 2026 · strength 0.24
  12. Surinder K. Batra · 1 shared paper, 2026 · strength 0.24
  13. Sushil Kumar · 1 shared paper, 2026 · strength 0.24
  14. Gregory M. Springett · 5 shared papers, 2011–2017 · strength 0.23
  15. Sarah E. Hoffe · 5 shared papers, 2011–2017 · strength 0.23
  16. Saı̈d M. Sebti · 4 shared papers, 2013–2017 · strength 0.21
  17. Domenico Coppola · 3 shared papers, 2012–2017 · strength 0.20
  18. Pamela Joy Hodul · 4 shared papers, 2011–2017 · strength 0.20
  19. David L. Morse · 1 shared paper, 2024 · strength 0.18
  20. Amanda Shanks Huynh · 1 shared paper, 2024 · strength 0.18
  21. Josef Vágner · 1 shared paper, 2024 · strength 0.18
  22. Dung‐Tsa Chen · 4 shared papers, 2012–2016 · strength 0.18
  23. Ravi Shridhar · 3 shared papers, 2016–2017 · strength 0.17
  24. Robert J. Gillies · 1 shared paper, 2024 · strength 0.16
  25. Shari Pilon-Thomas · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.